Fifteen novel natural ligands and three established AD reference drugs (donepezil, memantine, and rivastigmine) were assessed against four key AD proteins: sortilin, clusterin, Aβ peptide, and tau. The gene discussed is MAPT; the disease is Alzheimer disease.